Insmed (NASDAQ:INSM) Price Target Raised to $110.00

Insmed (NASDAQ:INSM) had its target price raised by UBS Group from $105.00 to $110.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. UBS Group’s target price indicates a potential upside of 46.88% from the company’s current price.

INSM has been the subject of a number of other research reports. JPMorgan Chase & Co. raised their price objective on Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research report on Friday, February 7th. Morgan Stanley lifted their target price on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. Truist Financial lifted their target price on Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a report on Friday, February 21st. HC Wainwright reissued a “buy” rating and issued a $90.00 target price on shares of Insmed in a report on Friday, February 21st. Finally, Guggenheim reissued a “buy” rating and issued a $101.00 target price on shares of Insmed in a report on Tuesday, February 25th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $93.33.

Insmed Stock Down 0.2 %

INSM stock opened at $74.89 on Thursday. Insmed has a twelve month low of $21.92 and a twelve month high of $84.91. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The firm has a market cap of $13.56 billion, a PE ratio of -13.40 and a beta of 1.28. The business has a 50 day moving average of $75.66 and a 200 day moving average of $73.83.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. On average, research analysts forecast that Insmed will post -4.56 EPS for the current fiscal year.

Insider Transactions at Insmed

In related news, CEO William Lewis sold 18,750 shares of Insmed stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $77.79, for a total transaction of $1,458,562.50. Following the transaction, the chief executive officer now directly owns 334,186 shares in the company, valued at approximately $25,996,328.94. The trade was a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Sara Bonstein sold 3,470 shares of Insmed stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $65.70, for a total value of $227,979.00. Following the transaction, the chief financial officer now owns 114,736 shares in the company, valued at $7,538,155.20. This trade represents a 2.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 550,957 shares of company stock worth $42,859,028 in the last ninety days. Insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On Insmed

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Insmed during the fourth quarter valued at $6,798,000. Mackenzie Financial Corp lifted its position in Insmed by 12.5% during the fourth quarter. Mackenzie Financial Corp now owns 10,883 shares of the biopharmaceutical company’s stock valued at $751,000 after purchasing an additional 1,213 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Insmed during the fourth quarter valued at $259,000. Fourth Dimension Wealth LLC purchased a new position in Insmed during the fourth quarter valued at $278,000. Finally, Vise Technologies Inc. lifted its position in shares of Insmed by 6.3% in the fourth quarter. Vise Technologies Inc. now owns 5,634 shares of the biopharmaceutical company’s stock valued at $389,000 after acquiring an additional 336 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.